MedPath

A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder

Phase 2
Conditions
autism spectrum disorder
Registration Number
JPRN-UMIN000007250
Lead Sponsor
Research Center for Child Mental Development, Kanazawa University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. History of allergy for oxytocin 2. History of traumatic brain injury with loss of consciousness for more than 5 minutes 3. Diagnosed as having substance dependence or history of substance dependence 4. History of water intoxication 5. Routinely severe polydipsia 6. Clinical judgment of ineligility for some reason

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath